Business briefs: Otsuka, GSK, California health exchanges

Share this article:

Japanese drugmaker Otsuka said today it will buy Astex Pharmaceuticals for $886 million. Astex reported positive Phase II mid-stage results last month for its bone cancer treatment. Currently, Astex has one approved drug, Dacogen, which treats myelodysplastic syndromes—a blood disorder.

A melanoma vaccine from British drugmaker GSK fell short in late-stage trials. The treatment, MAGE-A3, did not extend disease-free survival compared to placebo—failing to meet its primary endpoint.

Health exchange consumers in California will be able to compare prices online, the Los Angeles Times reported. An online tool lets consumers see price information for all plans sold in their area.

Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.